Parkinson's disease and CYP2D6 polymorphism in Asian populations: A meta-analysis

Neuroepidemiology

Volumn 22, Issue 6, 2003, Pages 357-361

  Persad, Amanda S ^a   Stedeford, Todd ^b,c   Tanaka, Seigo ^b   Chen, Liping ^b   Banasik, Marek ^c  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Cytochrome P 450 IID6; Debrisoquine; Debrisoquine 4 hydroxylase; Neurodegenerative diseases

Indexed keywords

CYTOCHROME P450 2D6; PROTEIN;

ALLELE; ARTICLE; ASIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; ETHNOLOGY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; LANGUAGE; MEDLINE; META ANALYSIS; METABOLISM; NOMENCLATURE; PARKINSON DISEASE; PHENOTYPE; POPULATION RESEARCH; PUBLICATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 0142089101     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072926     Document Type: Article

References (40)

1. Nagatsu T: Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res 1997;29:99-111.
2. Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR: Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994;36:100-103.
3. Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S: A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 2000;21:435-440.
4. Wang W-z, Fang X-h, Cheng X-m, Jiang D-h, Lin Z-j: A case-control study on the environmental risk factors of Parkinson's disease in Tianjin, China. Neuroepidemiology 1993;12:209-218.
5. Preux PM, Condet A, Anglade C, Druet-Cabanac M, Debrock C, Macharia W, Couratier P, Boutros-Toni F, Dumas M: Parkinson's disease and environmental factors. Matched case-control study in the Limousin region, France. Neuroepidemiology 2000;19:333-337.
6. Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
7. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J: Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985;2:1213-1216.
8. Hubble JP, Kurth JH, Glatt SL, Kurth MC, Schellenberg GD, Hassanein RES, Lieberman A, Koller WC: Gene-toxin interaction as a putative risk factor for Parkinson's disease with dementia. Neuroepidemiology 1998;17:96-104.
9. Tanaka S, Chen X, Xia Y, Kang DE, Matoh N, Sundsmo M, Thomas RG, Katzman R, Thal LJ, Trojanowski JQ, Saitoh T, Ueda K, Masliah E: Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease. Neurology 1998:50:1556-1562.
10. McCann SJ, Pond SM, James KM, Le Couteur DG: The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: A case-control study and meta-analysis. J Neurol Sci 1997;153:50-53.
11. Corrigan FM, Murray L, Wyatt CL, Shore RF: Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp Neurol 1998;150:339-342.
12. Corrigan FM, Wienburg CL, Shore RF, Daniel SE, Mann D: Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health A 2000;59:229-234.
13. Gonzalez FJ: The CYP2D subfamily; in Ioannides C (ed): Cytochrome P450: Metabolic and Toxicological Aspects. Boca Raton, CRC Press, 1996, pp 183-210.
14. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzales FJ: The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989;45:889-904.
15. 450 CYP2D locus. Nature 1990;347:773-776.
16. Modi S, Gilham DE, Sutcliffe MJ, Lian L-Y, Primrose WU, Wolf CR, Roberts GCK: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6:Allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 1997;36:4461-4470.
17. Kondo I, Kanazawa I: Debrisoquine hydroxylase and Parkinson's disease. Adv Neurol 1993;60:338-342.
18. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA: Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990;265:17209-17214.
19. Wang S-L, Huang J-d, Lai M-D, Liu B-H, Lai M-L: Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-418.
20. Tsuneoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichikawa Y: A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease. J Biochem (Tokyo) 1993;114:263-266.
21. Chan DKY, Woo J, Ho SC, Pang CP, Law LK, Ng PW, Hung WT, Kwok T, Hui E, Orr K, Leung MF, Kay R: Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J Neurol Neurosurg Psychiatry 1998;65:781-784.
22. Lo H-S, Chen C-H, Hogan EL, Kao K-P, Wang V, Yan S-H: Genetic polymorphism and Parkinson's disease in Taiwan: Study of debrisoquine 4-hydroxylase (CYP2D6). J Neurol Sci 1998;158:38-42.
23. Pang CP, Zhang J, Woo J, Chan D, Law LK, Tong SF, Kwok T, Kay R: Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease. Mov Disord 1998;13:529-532.
24. Tsuneoka Y, Matsuo Y, Ichikawa Y, Watanabe Y: Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease. Metabolism 1998;47:94-96.
25. Chida M, Yokoi T, Kosaka Y, Chiba K, Nakamura H, Ishizaki T, Yokota J, Kinoshita M, Sato K, Inaba M, Aoki Y, Gonzalez FJ, Kamataki T: Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics 1999;9:601-605.
26. Ho S-L, Kung MHW, Li LSW, Lauder IJ, Ramsden DB: Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians. Eur J Neurol 1999;6:323-329.
27. Iwahashi K, Yoshihara E, Nakamura K, Ameno K, Watanabe M, Tsuneoka Y, Ichikawa Y, Igarashi K: CYP2D6 HhaI genotype and the neuroleptic malignant syndrome. Neuropsychobiology 1999;39:33-37.
28. Woo SI, Kim JW, Seo HG, Park CH, Han SH, Kim SH, Kim KW, Jhoo JH, Woo JI: CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population. Psychiatry Clin Neurosci 2001;55:373-377.
29. Tao E, Liu Z, Chen B, Pan X, Shao M: Association between the debrisoquine hydroxylase gene polymorphism and the genetic susceptibility of Parkinson's disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 1998;15:281-283.
30. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR: Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.
31. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, Sturman SG, Schapira AHV, Williams AC, Spurr NK, Wolf CR: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
32. Diederich N, Hilger C, Goetz CG, Keipes M, Hentges F, Vieregge P, Metz H: Genetic variability of the CYP2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996;40:463-465.
33. Bordet R, Broly F, Destée A, Libersa C, Lafitte JJ: Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease. Clin Neuropharmacol 1996;19:213-221.
34. Gasser T, Müller-Myhsok B, Supala A, Zimmer E, Wieditz G, Wszolek ZK, Vieregge P, Bonifati V, Oertel WH: The CYP2D6B allele is not over-represented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:518-520.
35. Lucotte G, Turpin J-C, Gerard N, Panserat S, Krishnamoorthy R: Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families. Am J Med Genet 1996;67:361-365.
36. Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, Kinoshita M, Sato K, Gonzalez FJ, Kamataki T: A new CYP2D6 allele with a ninebase insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 1996;6:395-401.
37. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, Eichelbaum M: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001;11:573-585.
38. Jover R, Bort R, Gómez-Lechón MJ, Castell JV: Re-expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett 1998;431:227-230.
39. Cairns W, Smith CAD, McLaren AW, Wolf CR: Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family. J Biol Chem 1996; 271:25269-25276.
40. Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, Gonzalez FJ: The CYP2D6 humanized mouse: Effect of the human CYP2D6 transgene and HNF4α on the disposition of debrisoquine in the mouse. Mol Pharmacol 2001;60:1260-1267.